biote Corp. (BTMD) Stock
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About biote Corp.
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
biote Corp. is led by CEO Bret Christensen, employs 217 people, headquartered in US, publicly traded since 2021.
biote Corp. (BTMD) stock trades at $2.36 with a market capitalization of $104.09M. The stock is valued at a price-to-earnings (P/E) ratio of 4.58, price-to-book of -1.25, price-to-sales of 0.53. Over the past 52 weeks the stock has ranged between $1.27 and $4.75, and currently trades 50.3% below its 52-week high.
On profitability, biote Corp. generates a return on equity (ROE) of -22.91%, return on capital employed of 47.74%, an operating margin of 20.31%, a net profit margin of 8.29%.
Official website: biote.com